StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) income statement

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.77−0.01 (-0.10%)

Close on Nov 18, 2026Market cap $1.37BP/E –Yield –

Intellia Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-711.7%
Net margin
-672.2%
Return on equity, FY2025
-53.5%

Financial strength

Current ratio
6.65
Debt to equity
–
Debt to assets
–
Cash to current liabilities
133.7%

Valuation

P/E ratio
–
Price to sales
23.01
Price to book
1.88
Dividend yield
–

See a number that looks wrong?